Determining Therapeutic Efficacy of AGE in AD
确定 AGE 在 AD 中的治疗效果
基本信息
- 批准号:6848349
- 负责人:
- 金额:$ 19.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-02-01 至 2006-01-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs diseaseamyloid proteinsangiospermsapoptosisbehavior testcysteine endopeptidasesdietary supplementsenzyme linked immunosorbent assaygel mobility shift assaygenetically modified animalshippocampusimmunocytochemistryinflammationinterleukin 1laboratory mouseneuropathologyneuropsychologynitric oxide synthasenuclear factor kappa betaoxidative stressplant extractstumor necrosis factor alpha
项目摘要
DESCRIPTION (provided by applicant): Based on the fact that genesis of A-beta derived from amyloidogenic processing of APP is a key event in Alzheimer's pathogenesis including inflammation, and that cholesterol homeostasis and cholinergic system regulate APP processing, current Alzheimer's therapy targets cholinergic enhancement [Tacrine, Aricept/Donezepil, Rivastigmine, Galantamine]; and regulation of inflammation by NSAIDs [Aspirin, Ibuprofen, Indomethacin]; COX-2 inhibitors [Celebrex, Vioxx]. These drugs exert serious side effects including gastrointestinal bleeding, liver and renal toxicity, nausea, and are not effective with patients carrying ApoE gene 1. Current investigational drugs include Xanthine derivatives-Propentofylline and cholesterol-lowering agents [HMG-CoA reductase inhibitors-Statins]. Although some statins are shown to be anti-amyloidogenic, few clinical trials with statins are non-conclusive due to their proinflammatory nature/39. In this respect, natural alternative(s) with pleiotropic useful properties and with least adverse effects may provide greater therapeutic benefit over single-ingredient synthetic pharmaceutical drugs having serious side effects. One such alternative is garlic. Aged garlic extract (AGE) contains multipotent phytochemicals. S-Allyl-Cystein (SAC) component of AGE inhibits NFkAPPAB, TNFalpha, IL-1Beta 3, 20, and iNOS/24. Our preliminary data show that AGE reduced TNFalpha and IL-1Beta in Tg2576 in a dose-dependent manner. SAC and Diallyl disulfide (DADS) components of AGE are natural HMG-CoA reductase inhibitors 34/46. Our preliminary data show that AGE reduced cerebral amyloid in AIzheimer's transqenic model (Tg2576). In addition, AGE is known to be free-radical scavenger that enhances anti-oxidant enzymes (SOD, catalase and glutathione reductase) 3, inhibits lipid peroxidation 20, inhibits A-beta-induced apoptosis and improves memory deficits in senescence-accelerated mice. Thus, AGE is a natural "NSAID, Statin, anti-oxidant and anti-apoptotic agent"-a combination of many single-ingredient synthetic pharmaceutical drugs currently used for Alzheimer's therapy. However, the validity of AGE as Alzheimer's therapy has not been explored. This project is to determine pleiotropic effects of AGE in Alzheimer's Swedish double mutant (K670M/N671L) model (Tg2576).
Hypothesis: Multi-potent natural alternative AGE will prevent or reverse AD-like pathology and ameliorate behavioral deficits in Tg2576.
Specific Aims: [1] Determine if dietary AGE will promote non-amyloidogenic processing and reduce pre-existing amyloid burden in Tg2576; [2] Determine if dietary AGE will attenuate A-beta-induced inflammatory cascade in Tg2576; [3] Determine if dietary AGE will inhibit apoptosis in Tg2576; [4] Determine if dietary AGE will improve hippocampal-based Morris Water Maze performance in Tg2576.
Significance: Current AD-treatment utilizing cholinergic enhancers and NSAIDs is limited due to their adverse side effects and do not modify the disease process. If successful, this project will validate the use of safe, naturally well-tolerated, cost-effective and alternative herbal pharmacotherapy for treating AD.
描述(由申请人提供):基于以下事实,即源自APP的淀粉样蛋白生成加工的A-β的生成是阿尔茨海默病发病机制(包括炎症)中的关键事件,并且胆固醇稳态和胆碱能系统调节APP加工,当前阿尔茨海默病治疗靶向胆碱能增强[他克林、安理申/多奈泽匹尔、卡巴拉汀、加兰他敏];以及通过NSAID [阿司匹林、依维柯、吲哚美辛];考克斯-2抑制剂[西乐葆、万络]调节炎症。这些药物会产生严重的副作用,包括胃肠道出血、肝和肾毒性、恶心,并且对携带ApoE基因1的患者无效。目前的研究药物包括黄嘌呤衍生物-丙戊茶碱和降胆固醇药物[HMG-CoA还原酶抑制剂-他汀类药物]。尽管一些他汀类药物被证明具有抗淀粉样蛋白生成作用,但由于其促炎性质,很少有他汀类药物的临床试验是非决定性的/39。 在这方面,具有多效性有用特性和最少副作用的天然替代物可以提供比具有严重副作用的单一成分合成药物更大的治疗益处。其中一种替代品是大蒜。老化大蒜提取物(AGE)含有多能植物化学物质。AGE的S-烯丙基-半胱氨酸(SAC)组分抑制NF κ B、TNF α、IL-1 β 3、20和iNOS/24。我们的初步数据显示AGE以剂量依赖性方式降低Tg 2576中的TNF α和IL-1 β。AGE的SAC和二烯丙基二硫化物(DADS)组分是天然HMG-CoA还原酶抑制剂34/46。 我们的初步数据显示AGE减少了AIIB的转基因模型(Tg 2576)中的脑淀粉样蛋白。 此外,已知AGE是自由基清除剂,可增强抗氧化酶(SOD、过氧化氢酶和谷胱甘肽还原酶)3、抑制脂质过氧化20、抑制A-β诱导的细胞凋亡并改善加速衰老小鼠的记忆缺陷。因此,AGE是一种天然的“NSAID,他汀类药物,抗氧化剂和抗凋亡剂”-目前用于阿尔茨海默氏症治疗的许多单一成分合成药物的组合。然而,AGE作为阿尔茨海默氏症治疗的有效性尚未被探索。本课题旨在研究AGE对阿尔茨海默病瑞典双突变体(K670 M/N671 L)模型(Tg 2576)的多效性作用。
假设:多能天然替代AGE将预防或逆转AD样病理并改善Tg 2576中的行为缺陷。
具体目标:[1]确定饮食AGE是否会促进Tg 2576中的非淀粉样蛋白生成加工并减少预先存在的淀粉样蛋白负荷; [2]确定饮食AGE是否会减弱Tg 2576中A-β诱导的炎症级联反应; [3]确定饮食AGE是否会抑制Tg 2576中的细胞凋亡; [4]确定饮食AGE是否会改善Tg 2576中基于坎贝尔的Morris水迷宫性能。
重要性:目前使用胆碱能增强剂和NSAID的AD治疗由于其不良副作用而受到限制,并且不能改变疾病过程。如果成功,该项目将验证使用安全,自然耐受性良好,具有成本效益和替代草药药物治疗AD。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Multiplicity of garlic health effects and Alzheimer's disease.
大蒜对健康的多重影响和阿尔茨海默病。
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Chauhan,NB
- 通讯作者:Chauhan,NB
Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
阿尔茨海默病转基因小鼠模型的脑室内被动免疫。
- DOI:10.1586/14760584.3.6.717
- 发表时间:2004
- 期刊:
- 影响因子:6.2
- 作者:Chauhan,NeelimaB;Siegel,GeorgeJ
- 通讯作者:Siegel,GeorgeJ
Anti-amyloidogenic effect of Allium sativum in Alzheimer's transgenic model Tg2576.
- DOI:10.1080/j157v03n01_05
- 发表时间:2003-01-01
- 期刊:
- 影响因子:0
- 作者:Chauhan, Neelima B.
- 通讯作者:Chauhan, Neelima B.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NEELIMA CHAUHAN其他文献
NEELIMA CHAUHAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NEELIMA CHAUHAN', 18)}}的其他基金
Therapeutic Efficacy of Intranasal WGA-GLP1 in AD
鼻内WGA-GLP1治疗AD的疗效
- 批准号:
8512104 - 财政年份:2013
- 资助金额:
$ 19.48万 - 项目类别:
Therapeutic Efficacy of Intranasal WGA-GLP1 in AD
鼻内WGA-GLP1治疗AD的疗效
- 批准号:
8640998 - 财政年份:2013
- 资助金额:
$ 19.48万 - 项目类别:
Neuroregenerative Effects of Simvastatin in TBI
辛伐他汀对 TBI 的神经再生作用
- 批准号:
8974190 - 财政年份:2013
- 资助金额:
$ 19.48万 - 项目类别:
Neuroregenerative Effects of Simvastatin in TBI
辛伐他汀对 TBI 的神经再生作用
- 批准号:
9162263 - 财政年份:2013
- 资助金额:
$ 19.48万 - 项目类别:
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in AD
WGA 作为 AD 中抗 A-β 抗体鼻内递送的新型载体
- 批准号:
8091181 - 财政年份:2011
- 资助金额:
$ 19.48万 - 项目类别:
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in AD
WGA 作为 AD 中抗 A-β 抗体鼻内递送的新型载体
- 批准号:
8432312 - 财政年份:2011
- 资助金额:
$ 19.48万 - 项目类别:
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in AD
WGA 作为 AD 中抗 A-β 抗体鼻内递送的新型载体
- 批准号:
8246405 - 财政年份:2011
- 资助金额:
$ 19.48万 - 项目类别:
Reduction of Amyloid Burden by Antisense APP
通过反义 APP 减少淀粉样蛋白负担
- 批准号:
6780661 - 财政年份:2004
- 资助金额:
$ 19.48万 - 项目类别:
Determining Therapeutic Efficacy of AGE in AD
确定 AGE 在 AD 中的治疗效果
- 批准号:
6702792 - 财政年份:2004
- 资助金额:
$ 19.48万 - 项目类别:
Reduction of Amyloid Burden by Antisense APP
通过反义 APP 减少淀粉样蛋白负担
- 批准号:
6864811 - 财政年份:2004
- 资助金额:
$ 19.48万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 19.48万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 19.48万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 19.48万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 19.48万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 19.48万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 19.48万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 19.48万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 19.48万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 19.48万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 19.48万 - 项目类别:














{{item.name}}会员




